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Nonalcoholic fatty liver disease (NAFLD) prevalence is increasing worldwide, with the affected US population estimated near 30%. Diet is a recognized risk
factor in the NAFLD spectrum, which includes nonalcoholic steatohepatitis (NASH) and fibrosis. Low hepatic copper (Cu) was recently linked to clinical NAFLD/
NASH severity. Simple sugar consumption including sucrose and fructose is implicated in NAFLD, while consumption of these macronutrients also decreases liver
Cu levels. Though dietary sugar and low Cu are implicated in NAFLD, transcript-level responses that connect diet and pathology are not established. We have
developed a mature rat model of NAFLD induced by dietary Cu deficiency, human-relevant high sucrose intake (30% w/w) or both factors in combination.
Compared to the control diet with adequate Cu and 10% (w/w) sucrose, rats fed either high-sucrose or low-Cu diet had increased hepatic expression of genes
involved in inflammation and fibrogenesis, including hepatic stellate cell activation, while the combination of diet factors also increased ATP citrate lyase and
fatty acid synthase gene transcription (fold change N2, Pb0.02). Low dietary Cu decreased hepatic and serum Cu (P≤0.05), promoted lipid peroxidation and
induced NAFLD-like histopathology, while the combined factors also induced fasting hepatic insulin resistance and liver damage. Neither low Cu nor 30% sucrose
in the diet led to enhanced weight gain. Taken together, transcript profiles, histological and biochemical data indicate that low Cu and high sucrose promote
hepatic gene expression and physiological responses associated with NAFLD and NASH, even in the absence of obesity or severe steatosis.
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Casein 149.10 149.10 149.10 149.10
Sucrose 310.90 310.60 100.00 100.00
Maltose dextrin 0.00 0.00 155.90 155.90
Corn starch 410.00 410.00 465.00 464.70
Cellulose 40.00 40.00 40.00 40.00
Salt mix, 76, Cu-def 35.00 35.00 35.00 35.00
Vit. mix, 76A 10.00 10.00 10.00 10.00
DL-Methionine 3.00 3.00 3.00 3.00
Choline bitartrate 2.00 2.00 2.00 2.00
Cu carbonate 0.00 0.22 0.00 0.22
Corn oil 40.00 40.00 40.00 40.00
FD&C red 0.00 0.08 0.00 0.08
Total mass 1000.00 1000.00 1000.00 1000.00
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[5]. Nonalcoholic fatty liver disease (NAFLD), the hepatic manifesta-
tion of MetS, is likewise becoming more prevalent; it is the most
frequently diagnosed liver disease in Western countries as well as a
health disparity for someminority groups [6]. It is currently estimated
that, in developed countries, 25%–30% of adults [7–10] and 3%–10% of
children [11] have NAFLD. The emergence of pediatric NAFLD may be
particularly alarming as the diagnosis can include progression to
cirrhosis [12]. NAFLD includes a spectrum of liver pathology ranging
from simple steatosis to nonalcoholic steatohepatitis (NASH), ﬁbrosis
and cirrhosis [13]. First identiﬁed in 1980s, the cause of the disease is
still unknown [14]. Recent studies have suggested that progression to
NASH may increase mortality risk [15], while ﬁbrosis severity is a
critical diagnostic tool for chronic liver disease [16,17] and indicative
of long-term liver complications and enhanced mortality risk [18,19].
The molecular mechanisms driving NAFLD progression to NASH have
remained elusive, although NAFLD patients presenting with any
degree of systemic inﬂammation and any degree of ﬁbrosis are
thought to be at highest risk for NASH [15].
This complex systemic manifestation describes an integrative
metabolic response during NAFLD. In this context, the dietary status of
the micronutrient copper (Cu) has a fundamental inﬂuence on lipid
metabolism, although the underlying mechanisms of inﬂuence are
unclear (for review see Ref. [20]). Currently, the American orWestern
diet may be low in essential dietary nutrients such as Cu [21]. Cu
deﬁciency induces NAFLD symptoms in rodent models [22–25], and
retrospective analysis of NAFLD patients revealed decreased hepatic
Cu levels that correlated with NAFLD/NASH progression [22,23].
Additionally, NAFLD patientswith lowCu displayed increased levels of
hepatic iron [22]. Biopsies from NAFLD patients with hepatic iron
overload also revealed an association with increased oxidative stress
and NASH [26]. In vivo rodent models of dietary Cu deﬁciency also
displayed increased hepatic iron content, [22] as well as steatosis and
insulin resistance [23]. Intestine-speciﬁc genetic inactivation of high-
afﬁnity Cu import also resulted in Fe accumulation in the liver in
Kupffer cells, linking intestinal Cu transport and altered hepatic Fe
metabolism [27].
In addition to Cu, another nutrient that affects NAFLD is dietary
sugar, including fructose and sucrose. High fructose consumption,
potentially from high-fructose corn syrup (HFCS) in beverages, is
implicated as a factor driving the metabolic dysregulation underlying
MetS. HFCS includes fructose in roughly equal proportion to glucose,
similar to the 1:1 ratio in sucrose, and both sugar sources have
equivalentmetabolic effects despite recentpublic focus on fructose [28].
Consumptionof fructose in theUnitedStates has increased over thepast
30 years, possibly by asmuch as 25% [29], via food sources such as fruit
juice and HFCS in soft drinks [30,31]. Recent estimates place the mean
fructose consumption among Americans at 10% of dietary intake and as
high as 15% in up to one fourth of adolescents [29,30]. Approximately
10% of adults consume asmany as 25% of their daily calories from added
sugar [32]. Importantly, an indirect role of fructose in oxidative stress
may be occurring via the down-regulation of the Ctr1 Cu importer, as
indicated in a weanling rat model of NAFLD [24], whereby low Cu
reduces antioxidant capacity by limiting Cu-Zn superoxide dismutase
activity and promoting hepatic iron accumulation [33].
Two recent studies have assessed the combination of high-fructose
diets (30% or 3% fructose added to a standard puriﬁed diet that already
included 50% sucrose) with Cu-deﬁcient (CuD) diets in weanling rats
[24,25]. Interestingly, high fructose intake exacerbated both Cu
deﬁciency and hepatic iron overload, caused increased oxidative
stress and decreased antioxidant defenses. These experimental diets,
however, with the experimental AIN76A standard puriﬁed diet
formulation of 50% sucrose (and thus 25% fructose) diverge greatly
from human dietary patterns. Though the existing data support links
between dietary sugars, Cu status and NAFLD, the molecularmechanisms by which Cu deﬁciency and dietary sugars interact to
both induce and aggravate NAFLD/NASH disease progression
are unclear.
Thus,while a low-Cudiet is sufﬁcient to induce its deﬁciency and to
initiate lipogenesiswith subsequent NAFLD symptoms, lowhepatic Cu
may also be involved in aggravating inﬂammation to promote
progression of NAFLD to NASH, especially when coupled to excessive
fructose consumption. The goal of the present study is to test the
hypothesis that the liver transcriptomic response to suboptimal Cu
nutrition and Western-diet-relevant dietary sugar/fructose intake,
separately and in combination, can reveal gene expression pathways
by which the diet factors promote steatosis and NAFLD spectrum
symptoms in a mature rodent model. In our study, analysis of either
low Cu or 30% sucrose in the diet identiﬁed differentially expressed
genes involved in inﬂammatory and ﬁbrogenesis responses, while the
combination of both factors also caused up-regulation of fatty acid
synthesis genes despite fewer overall transcript changes compared to
the impact caused by either the low-Cu or high-sucrose diet.
Moreover, observation of differentially expressed genes correspond-
ing to a proﬁbrotic state, coupled with the development of insulin
resistance in rats fed the combined Cu-deﬁcient/30% sucrose diet,
indicates that lowdietary Cu and sucrose consumptions are previously
unrecognized, independent and synergistic risk factors contributing to
the progression of NAFLD.2. Methods
2.1. Animal husbandry and tissue collection
Animal experiments and husbandry were reviewed and approved
by theUniversity of Alaska Anchorage (UAA) Institutional Animal Care
and Use Committee and performed in accordance with US Public
Health Service Policy as documented by The Guide for the Care and Use
of Laboratory Animals, Eighth Edition [34]. Mature (6 months old)male
Wistar Rats that had been allowed ad libitum access to Mazuri Rodent
Diet (PMI Nutrition, St. Louis, MO, USA) were used in the study.
Twenty-four rats were randomly assigned to one of four groups and
fed for 12 weekswith diets based on the Puriﬁed AIN76A formulation,
modiﬁed for target sucrose and Cu content as indicated in Table 1
(Custom Animal Diets, Bangor, NJ, USA). Sucrose and Cu contents in
diets were as follows: CuD/30% — Cu deﬁcient (b0.3 mg Cu/kg)/30%
sucrose, CuA/30% — Cu adequate (125 mg/kg)/30% sucrose, CuD/10%
— b0.3 mg/kg Cu/10% sucrose and CuA (125 mg/kg Cu)/10% sucrose
(control). Starch and dextrin were used to equalize carbohydrates. Cu
levels were selected consistent with deﬁcient and “normal” Cu diets
used by Aigner et al. [23]. Cu content was veriﬁed by inductively
coupled plasma mass spectrometry (ICP-MS). All animals were kept
on a 12:12 light cycle with food and water supplied ad libitum. Rats
Table 2
IPA identiﬁed pathways with differentially expressed transcripts indicated for each test diet when compared to the control diet
Accession Symbol Name Signiﬁcant expression change in:
TNF family CuA/30% CuD/10% CuD/30%
NM_012675 Tnf Tumor necrosis factor (alpha) *
NM_212507 Ltb Lymphotoxin beta a.k.a. TNFc *
NM_001109112 Tnfsf13b B-cell activating factor * *
NM_145765 Tnfsf15 Vascular endothelial growth inhibitor * * *
NM_019135 Tnfrsf8 a.k.a. CD30 *
NM_001025773 Tnfrsf9 a.k.a. CD137 * *
NM_001108207 Tnfrsf21 Death receptor 6 * *
T helper cell cytokines/receptors
NM_201270 Il-4 Interleukin-4 (from Th2 cells) * *
NM_053828 Il-13 Interleukin-13 (from Th2 cells) *
NM_001191988 Il-22 Interleukin-22 (from Th17 cells) *
NM_013163 Il-2ra Interleukin-2 receptor alpha (ligand is from Th1 cells) * * *
NM_001191937 IL-17rd Interleukin-17 receptor d (ligand is from Th17 cells) *
NM_001012469 Il-21r Interleukin-21 receptor (ligands from Th2, Th17 cells) * *
NM_001191869 Il-22ra1 Interleukin-22 receptor alpha 1 (ligand is from Th17 cells) * *
Chemokines
NM_031530 Ccl2 C-C motif ligand 2 *
NM_013025 Ccl3 C-C motif ligand 3 *
NM_001007612 Ccl7 C-C motif ligand 7 *
NM_030845 Cxcl1 C-X-C motif ligand 1 *
NM_053647 Cxcl2 C-X-C motif ligand 2 *
NM_001017496 Cxcl13 C-X-C motif ligand 13 ↓
NM_017183 Cxcr2 C-X-C motif receptor 2 * *
Extravasation and inﬁltration
NM_001011889 Cldn9 Claudin 9 *
NM_053457 Cldn11 Claudin 11 *
NM_001107112 Cldn17 Claudin 17 *
NM_001008514 Cldn19 Claudin 19 *
NM_001109394 Cldn20 Claudin 20 *
ENSRNOT00000015940 Itga2 Integrin, alpha 2 *
NM_138879 Sele Selectin E * * *
NM_019177 Sell Selectin L *
NM_013114 Selp Selectin P *
ECM remodeling
ENSRNOT00000026719 Col6a3 Procollagen, Type VI, alpha 3 * *
NM_212528 Col11a2 Collagen, Type XI, alpha 2 *
HS6ST2 Hs6st2 Heparan sulfate 6-O-sulfotransferase 2 * *
XM_344461 Hs6st3 Heparan sulfate 6-O-sulfotransferase 3 * *
NM_001108237 Lama1 Laminin, alpha 1 * * *
NM_001105925 Mmp17 Matrix mettalopeptidase 17 *
XM_002742434 Mmp25 Matrix mettalopeptidase 25 * *
NM_031641 Sult4a1 Sulfotransferase family 4A, member 1 * *
NM_001109393 Timp4 Tissue inhibitor of MMP4 * *
Other inﬂammatory
NM_001029901 Csf1r Colony-stimulating factor 1 receptor * *
NM_133555 Csf2rb Colony-stimulating factor 2 receptor beta * *
NM_001106685 Csf3r Colony-stimulating factor 3 receptor * * *
NM_053953 Il-1r2 Interleukin-1 receptor 2 *
NM_001106418 Il-7r Interleukin-7 receptor *
NM_001191750 Il-12rb2 Interleukin-12 receptor beta 2 * *
NM_017208 Lbp Lipopolysaccharide binding protein *
NM_001006961 Osm Oncostatin M *
NM_001005384 Osmr Oncostatin M receptor * *
Hedgehog signaling pathway — EMT of HSCs
NM_001191910 Gli1 Gli family zinc ﬁnger 1 * * *
NM_001107169 Gli2 Gli family zinc ﬁnger 2 * *
NM_080405 Gli3 Gli family zinc ﬁnger 3 * ↓
Fibroblast proliferation and differentiation
NM_053809 Fgf4 Fibroblast growth factor 4 * *
NM_022211 Fgf5 Fibroblast growth factor 5 * * *
NM_130816 Fgf11 Fibroblast growth factor 11 * * *
NM_130751 Fgf22 Fibroblast growth factor 22 *
NM_130754 Fgf23 Fibroblast growth factor 23 * *
NM_031131 Tgfb2 Transforming growth factor beta 2 * *
NM_021586 Ltbp2 Latent transforming growth factor beta binding protein * *
Markers of HSC activation
NM_017009 Gfap Glial ﬁbrillary acidic protein *
NM_012604 Myh3 Myosin (II), heavy chain 3, skeletal muscle, embryonic * * *
NM_001106017 Myl7 Myosin light chain 7, regulatory * * *
XM_001078857 Myh13 Myosin (II), heavy chain 13, skeletal * *
NM_001100690 Myh14 Myosin (II), heavy chain 14, non-muscle *
NM_145879 Socs1 Suppressor of cytokine signaling 1 * *
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Table 2 (continued)
Accession Symbol Name Signiﬁcant expression change in:
Metabolism and MetS related
NM_012544 Ace Angiotensin-I-converting enzyme * *
NM_016987 Acly ATP-citrate lyase *
NM_001004085 Crat Carnitine O-acetyltransferase ↓
NM_031241 Cyp8b1 Cytochrome P450, family 8, subfamily b, polypeptide 1 ↓ ↓
NM_017332 Fasn Fatty acid synthase *
NM_023964 Gapdhs Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic * * *
NM_021669 Ghrl Ghrelin/obestatin prepropeptide * *
NM_001109615 Gys1 Glycogen synthase 1, muscle * * *
NM_001192008 Idi2 Isopentenyl-diphosphate delta isomerase 2 * *
NM_130741 Lcn2 Lipocalin 2 *
NM_012859 Lipe Lipase, hormone sensitive *
NM_017341 Lipf Gastric lipase *
NM_053994 Pdha2 Pyruvate dehydrogenase (lipoamide) alpha 2 *
NM_057135 Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 * * *
NM_013161 Pnlip Pancreatic lipase * *
NM_017136 Sqle Squalene epoxidase *
NM_001107846 Steap2 Six transmembrane epithelial antigen of the prostate 2 * * *
Each asterisk in the table indicates that a speciﬁc transcript was differentially expressed (up-regulated) compared to the control diet. A down-pointing arrow indicates a decrease in
transcript level compared to the control.
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12 weeks during the active (dark) period. Serum was isolated from
whole blood and frozen at−80 ° C. Livers were perfused with saline
via the hepatic portal vein prior to excision, and lobes were separated
and stored [frozen at −80 °C, or ﬁxed with 4% formaldehyde (Fisher
Chemical) in phosphate-buffered saline (PBS) (Sigma) for 1 week
followed by storage in PBS with 0.02% sodium azide].2.2. Gene expression
Hepatic RNA was isolated from ﬂash-frozen liver tissue using the
NucleoSpin RNA II kit (Machery-Nagel). Hepatic transcript proﬁles
(n=6 per diet treatment) were analyzed by individual Agilent
Sureprint G3 Rat 8X 60K platform according to standard protocols
through the Institute for Systems Biology (University of Washington,
Seattle, WA, USA). Features were extracted with Agilent Feature
Extraction and imported into GeneSpring (v12.6, Agilent Technolo-
gies, Inc.). Data were normalized by upper quartile rank (also called
percentile normalization). Transcript expression levels that changed
as a result of the experimental diets compared to control were
identiﬁed by a fold change (FC) greater than 2.0 and moderated t test
(Pb0.02) with Benjamini–Hochberg correction for multiple compar-
isons as this order of tests is reported to be both statistically stringent
whilemaintaining biological relevancewhen compared to either FC or
t test alone [35]. Differentially expressed transcripts and normalized
expression values are provided in Supplementary Tables S1–S3.
Transcript expression levels that met these criteria were separated
into lists of those unique to each diet and those shared between diets,
andwere analyzed in terms ofmetabolic networks using the Ingenuity
Pathways Analysis (IPA, Ingenuity® Systems) software. Top Canonical
Pathways and Top Tox Functions in IPA were used to examine
metabolic pathways and biological functions that are impacted as
suggested by altered transcript expression levels. Select transcripts of
interest from pathways represented by IPA were veriﬁed in silico by
comparison to existing literature describing NAFLD/NASH, as well
as quantitative reverse transcription polymerase chain reaction
(qRT-PCR) (primers are listed in Supp. Table S4). The WebGestalt
platform [36] was used to search for enriched gene ontology (GO)
terms in the differentially expressed gene sets from the different
comparisons, using as a reference list the set of rat genes represented
in themicroarrayused. GO termswithBenjamini–Hochberg-corrected
P values b0.05 were selected as enriched [37].Raw qPCR ampliﬁcation data were analyzed by LinRegPCR
(linregpcr.nl/ [38]). Relative quantiﬁcation used the comparative
ΔΔCt method with actin-beta and beta-2 macroglobulin as reference
transcripts [39], expressed per gene as FC (2−ΔΔCt). Quantitative RT-PCR
proﬁles of inﬂammatory transcripts were performed by SA Biosciences
RT2 Cytokines and Chemokines Rat PCR array.
2.3. Gene nomenclature
Gene symbols referring speciﬁcally to expression in the rat model
are consistent with the Rat Genome Database (http://rgd.mcw.edu/)
and are matched with human orthologs deﬁned by the HUGO Gene
Nomenclature Committee (www.genenames.org). Gene symbols
discussing expression in multiple species or human cells/tissue follow
the HUGO nomenclature. Accession numbers are included in Table 2.
2.4. Histology
Parafﬁn-embedded or frozen liver samples were sectioned and
stained with hematoxylin and eosin (H&E) and oil red O (ORO) stains.
Whole-slide images of eachOROandH&E tissue sectionwere captured
by Olympus NanoZoomer Digital Pathology Microscope. ORO images
were captured near hepatic portal triads using NDP software at 200×
magniﬁcation and divided into quadrants. Quadrantswere codedwith
a randomnumeral to eliminate bias during evaluation, andNIH ImageJ
was used to attain digital image analysis (DIA) of % stained area. H&E
imageswere used to determine presence of histological characteristics
including lymphocyte inﬁltration, potential Mallory–Denk bodies and
ballooning hepatocytes features [2,40]. Coherent anti-Stokes Raman
scattering spectroscopy (CARS) was performed by Dr. T. Le (Desert
Research Institute) as described in Ref. [41].
2.5. Biochemical analyses
Concentrations of serum glucose and serum insulin were deter-
mined using a glucose ﬂuorometric assay kit (Cayman Chemical) and
rat insulin enzyme immunoassay kit (SPI-bio), respectively. To assess
insulin resistance, a homeostatic model assessment of insulin
resistance (HOMA-IR) modiﬁed speciﬁcally for Wistar rats [42] was
used as a mathematical model deﬁning insulin resistance based on
serum glucose and insulin concentration. Serum alanine transaminase
level (ALT) was measured using a colorimetric assay kit (Cayman
Fig. 1. Relationships of transcript proﬁles and qRT-PCR analysis of selected transcripts. (A)
Venndiagram indicatingoverlapof transcripts andnumbers incategories forCuD/30%, CuA/
30% and CuD/10% compared to control CuA/10% diet. (B) Mean FC (2−ΔΔCt) for CuD/30%,
CuA/30% and CuD/10% compared to CuA/10% with S.E.M. is shown (n=3 per treatment).
Fig. 2. CuD or high sucrose initiates transcript expression associated with inﬂammation.
Cytokines and chemokines qPCR array showing the number of transcripts with FC N1.5
up or down compared to CuA/10% diet.
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EnzyChrom Triglyceride Assay Kit from BioAssay Systems. Malondial-
dehyde (MDA) concentrations in serum and hepatic tissue homoge-
nates were determined using a thiobarbituric acid reactive substances
(TBARS) assay (Cayman Chemical). Free fatty acid (FFA) concentra-
tions were determined using ﬂuorometric assays for oleic acid
(Cayman Chemical) and palmitic acid (BioAssay Systems).2.6. Elemental analysis
Approximately 30 mg of hepatic tissue was dehydrated for 24 h at
37°C, after which tissue samples and serum were analyzed for
transition metal content using ICP-MS by the Elemental Analysis
Core at the Oregon Health & Science University in Portland, OR, USA.2.7. Statistical analysis
Elemental, biochemical and quantiﬁed histological data have been
expressed as means with error bars representing standard error of the
mean (±S.E.M.). Statistical analyses of biochemical, histological and
elemental data were carried out using the GraphPad Prism software
and included either Student’s t test when comparing only two groups
or single-factor analysis of variance (ANOVA) followedbyDunnett’s or
Šídák’s multiple-comparison test where appropriate [43]. ROUToutlier analysis [44] was used to eliminate outliers (two outliers in
liver Cu were eliminated).
3. Results
3.1. Lowdietary Cu andhigh sucrose induce transcript responses in signaling,
inflammation and fibrosis pathways in a mature rat model of NAFLD
Intersection of transcripts whose abundance was signiﬁcantly
altered as a result of each diet is showed in Fig. 1A. An extensive
overlap (n=420) in differentially expressed genes was observed
between all the studied diet treatments. This number covers more
than 70% of the transcriptional changes in the low Cu (CuD) combined
with 30% sucrose, indicating that the transcriptional response under
this diet scenario is principally covered by each of the conditions for
itself, where the particular common changes can be classiﬁed as a local
response, basically conﬁned to 60 genes. The preponderance (more
than 90%) of differentially expressed transcripts in each Venn diagram
sectionwasup-regulated (Supp. Table S5). The observation that nearly
all changed transcripts are up-regulated has also been observed in
human transcriptomic study of NAFLD, with 10 times as many up-
regulated compared to down-regulated transcript levels [45].
The differentially expressed transcripts for each dietwere analyzed
by gene set enrichment analysis, which analyzes whether a-priori-
deﬁned “sets” of biologically related genes are differentially repre-
sentedwhen comparing twogene lists [46] andGOenrichment using a
similar approach for deﬁned sets of ontologies. Enriched processes
identiﬁed across treatments in the GO analysis are characterized as
corresponding to genes involved in signal transduction processes,
particularly G-protein-coupled receptor signaling, as well as sodium
and potassium transport activity (Supp. Fig. S6–S8). The CuD/30% diet
also indicated response to Cu ion levels as well as monooxygenase
activity and arachidonic acid epoxygenase activity (Supp. Fig. S8).
To identify pathways with potential roles in NAFLD and associated
with genes that are differentially expressed in response to the diet
treatments, lists of differentially expressed transcripts in each diet
were compared to transcript expression patterns in the control (CuA/
10% sucrose) and analyzed with IPA’s Core Analysis and Canonical
Pathway functions. Transcripts of interest in each diet were selected
from IPA-represented pathways using comparisons to existing
literature on NAFLD progression. Of these, selected up-regulated
Fig. 3. Dietary CuD inﬂuences hepatic pathology and steatosis. (A) Representative ORO and H&E images of hepatic tissue with indicated diet (20× objective). CuD diets evidenced
signiﬁcant increases in lipid staining. (B) White arrowheads indicate possible Mallory–Denk bodies (20× objective, digital zoom 2×). (C) Digital image analysis of ORO-stained lipid
accumulation by % area, evaluated by ANOVA followed by Dunnett's multiple-comparison test. Data (columns) represent means±S.E.M. (n=6). (D) CARS imaging conﬁrms lipid
accumulation in 30%/CuD liver compared to 30%/CuA liver.
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(Fig. 1B). Transcriptsmapped to each IPA pathway are listed in Table 2
along with indication of differential expression levels for each diet.
Speciﬁc nutrient-transcription responses with potential links to
NAFLD and progression to NASH are described below.
3.2. Molecular profiles indicate immune cell infiltration in liver due to
dietary CuD or 30% sucrose
Single-variable diets (CuD/10% sucrose andCuA/30% sucrose)were
most signiﬁcantly represented in IPA’s Top Canonical Pathway
function by differentially expressed genes related to immune cell
adhesion and diapedesis pathways, sharing the up-regulation of
transcripts for claudins and selectins as well as transcripts involved in
extracellular matrix (ECM) tissue remodeling (Table 2). The CuD/10%
diet resulted uniquely in up-regulation of transcripts coding for the
collagen receptor alpha 2 integrin (Itga2). These results suggest that
the hepatic response to Cu deﬁciency or sucrose challenge in the diet
may include tissue remodeling and inﬁltration of immune cells.
3.3. Inflammation, fibrosis and proliferation transcripts are up-regulated
by 30% sucrose and low Cu
Consistent with immune cell inﬁltration and extravasation, Top
Canonical Pathways analysis revealed an increase in inﬂammatory
transcripts involved in the activation and proliferation of immune
cells. Both single-variable diets resulted in up-regulation of transcriptscorresponding to members of the tumor necrosis factor (TNF)
superfamily, interleukins (ILs) and colony-stimulating factor recep-
tors, while the CuA/30% sucrose diet uniquely increased several
transcripts in each category such as Tnfα as well as C-C motif
chemokines Ccl2 and Ccl3. Both CuA/30% and CuD/10% diets resulted
in the up-regulation of Il4 gene expression, while CuD/10% alone up-
regulated Il13. An additional T-helper cell proﬁle, the Th17 proﬁle, was
represented in both CuA/30% and CuD/10% by up-regulation of genes
coding for receptors of Il21 and Il22 and, in the CuA/30% diet alone, for
the receptor for Il17. Additional inﬂammation-related transcripts
were up-regulated in the single-factor CuA/30% and CuD/10%
diet treatments.
Signiﬁcant up-regulation of gene transcripts related to the
inﬂammatory response in the absence of severe steatosis was an
unexpected ﬁnding in this study. Therefore, a qPCR proﬁle of
inﬂammatory transcripts across diets was used to conﬁrm the
microarray-based observations. While both the CuD/10% diet and
the CuA/30% resulted in altered expression of transcripts related to
inﬂammation, the CuA/30% diet initiated the greatest patterns of
altered transcript expression levels overall, most notably those related
to the TNF and IL families (Fig. 2). Additionally, the gene coding for Il33
was signiﬁcantly up-regulated (FCN1.5 and Pb0.05, n=3) in the CuD/
10% diet. The CuD/30% diet, in contrast, had fewer up-regulated
inﬂammation-related transcripts compared to the CuA/10% sucrose
control diet, supporting the observation of a negative synergism in
gene expression patterns for the CuD/30% sucrose diet, where the
combination of factors has less of an effect than single factors (i.e., CuD
Fig. 4. Dietary CuD alters circulating triglyceride levels, but not fatty acids orweight gain.
(A) Serum TG concentration by dietary Cu content; 10% and 30% sucrose are grouped.
(B) Serum palmitic acid concentration. (C) Serum oleic acid concentration. (D) Weight
change after 12 weeks ad libitum feeding puriﬁed diets.
1002 S. Tallino et al. / Journal of Nutritional Biochemistry 26 (2015) 996–1006or 30% sucrose alone). The single-variable diets as well as the CuD/30%
diet resulted in up-regulation of hepatic inﬂammatory transcripts
compared to control, although the inﬂammatory proﬁles and relative
magnitude of gene expression response were different across diets.
Perhaps the most unexpected pattern of gene expression changes
involved the observed increase in transcripts related to ﬁbrosis
progression. All tested diets shared increased levels of some of the
ﬁbrosis-relevant transcripts indicative of hepatic stellate cell (HSC)
activation suchasﬁbroblast growth factors (FGFs) 5 and11andmyosins
Myh3 andMyl7. TheCuD/10%diet alone resulted in the up-regulation of
the genes coding for Fgf22 and the glial ﬁbrillary acidic protein (Gfap),
another possible marker for the earliest stages of HSC activation during
inﬂammation. This also suggests a speciﬁc HSC response to Cu
deﬁciency that may exacerbate or accelerate NAFLD progression. In
addition to up-regulation of the Gfap transcript in the CuD/10% diet, an
increase in transcript levels coding for the suppressor of cytokine
signaling 1 (Socs1), which is also associated with HSC activation, was
observed as a result of both CuA/30% and CuD/10% diets.
The two single-variable diets CuA/30% and CuD/10% resulted in
transcript level increases for the transforming growth factor beta,
isoform2 (Tgfb2) and its associated binding protein (Ltbp2), aswell as
for sulfotransferases involved in the ECM sulfation of glycosamino-
glycans related to Tgfb activation. Of the Hedgehog pathway effectors,
Gli1 transcript levels were increased in all three treatment diets, while
a Gli2 transcript increase was shared by single-variable diets, and Gli3
transcript was up-regulated in the CuA/30% diet alone. The combined
CuD/30% sucrose diet, however, induced signiﬁcant down-regulation
of the Gli3 transcript compared to the control CuA/10% diet.
3.4. Dietary sucrose and CuD alter transcripts involved in lipid
metabolism and MetS
Differentially expressed transcripts indicate that a CuD and 30%
sucrose diet signiﬁcantly affects hepatic metabolism. While the CuD/30% diet resulted in the fewest gene expression changes, the top
metabolic pathway uniquely affected by this diet involved acetyl-CoA
biosynthesis III (from citrate). The up-regulation of genes coding for
ATP citrate lyase (Acly) and fatty acid synthase (FASN) as a result of
the CuD/30% diet (Fig. 1B, Table 2) indicates a switch from
carbohydrate to lipid metabolism via use of excess citrate. All three
treatment diets shared an increase in glycogen synthase 1 (Gys1)
transcripts aswell as in transcripts involved in cellular citrate increase,
such as an isoform of glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) and6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
(Pfkfb3). Transcripts related to TG breakdown in the CuA/30% and
CuD/10%diets included pancreatic lipase (Pnlip),while CuD/10% alone
up-regulated hormone-sensitive lipase (Lipe) and CuA/30% sucrose
alone increased gastric lipase (LIPF). Mevalonate pathway transcripts
related to cholesterol synthesis were also up-regulated, including
increases in isopentenyl-diphosphate delta isomerase 2 (Idi2)
transcripts in both CuA/30% and CuD/10% diets, while the transcript
coding for squalene epoxidase (Sqle) was increased by the CuA/30%
diet. Other transcripts associated with MetS included increased gene
expression of the angiotensin-1-converting enzyme (Ace) in CuA/30%
and CuD/10% diets. Correspondingly, in the CuA/30%diet, we observed
increased lipocalin 2 (Lcn2) and decreased cytochrome p450 family 8
subfamily B1 (Cyp8b1) gene expression in both CuA/30% and CuD/30%
diets, while all three diets led to increased transcript levels of laminin
alpha 1 (Lama1) and the six-transmembrane epithelial antigen of the
prostate 2 (Steap2) metalloreductase. Thus, either dietary Cu
deﬁciency or high-sucrose diet induces a distinct transcript proﬁle
that is consistent with steatosis, NAFLD and NASH, while, combined,
the two dietary factors appear to favor a switch to lipogenic
metabolism, including Acly and Fasn.
3.5. Diets with 30% sucrose or low Cu promote histopathology consistent
with NAFLD and NASH and disrupt metal balance
Histological analysis indicated that rats fed with CuD or 30%
sucrose displayed at least some histological characteristics of NAFLD
compared to rats fed with the CuA/10% sucrose control diet (Fig. 3A).
The CuD/30% sucrose diet induced the most severe pathology, where
ballooned hepatocytes and structures consistent with Mallory–Denk
bodies were observed (Fig. 3B), along with some potential inﬂamma-
tory cell inﬁltration of the liver tissue indicated by areas with
numerous small, dark-stained cells. Although there is some expected
heterogeneity in pathology, close examination of liver tissue from the
CuD/30%-fed animals also reveals features suggestive of immune cell
inﬁltration in addition to apparent mild steatosis (not shown).
ORO lipid staining of hepatic sections followed by DIA was used in
this case to quantitatively analyze hepatic lipid accumulation. This
method has previously been shown to be the most accurate
histological method to determine hepatic lipid accumulation [47].
CuD/10% and CuD/30% diets signiﬁcantly increased the percentage of
stained area in rat hepatic tissue (Fig. 3C). Induction of steatosis by
CuD was conﬁrmed by quantitation of lipids using CARS liver tissue
sections from separate animals fed CuA/30% and CuD/30% diets
(Fig. 3D). These data indicate that CuD diets are sufﬁcient to induce
modest steatosis in mature rats by 12 weeks regardless of sucrose
content,while a combination of both Cu deﬁciency and sucrose dietary
factors induces more characteristic histological features of NAFLD
progression. No signiﬁcant differences were observed in serum TG
concentration across diets. However, when grouped by Cu content,
serum TG levels weremodestly but signiﬁcantly higher in rats fed CuD
diets (Fig. 4A). No signiﬁcant differences (PN0.05) in two tested fatty
acids, palmitic acid and oleic acid, were observed (Fig. 4B–C). Thus, Cu
deﬁciency slightly increased fasting circulation of TG by 12 weeks
without a concurrent increase in fasting serum FFA levels. No
signiﬁcant weight difference existed between rats fed experimental
Fig. 5. CuD and sucrose inﬂuence Cu and Fe status.Mean±S.E.M. (n=5–6) for hepatic Cu
(A) and Fe (B) and serum Cu (C) and Fe (D). Signiﬁcant differences between treatments
are indicated by asterisks (P≤.05).
Fig. 6. Individual and synergistic effects of CuD and sucrose on insulin resistance and
oxidative stress. (A) Serum glucose, (B) serum insulin, (C) modiﬁed HOMA-IR
evaluating insulin resistance: dotted and dashed lines indicate validated HOMA-IR
values for normal and insulin-resistant Wistar rats [42]. Levels of (D) hepatic and (E)
serumMDA as assessed by TBARS assay. (F) Serum ALT level. Mean±S.E.M. (n=5–6) is
indicated in A–F. Asterisks indicated signiﬁcance of data vs. control: *Pb.05, **Pb.01.
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low dietary Cu and high sucrose may act independently of obesity-
induced changes commonly observed with other NAFLD models. The
histological analysis of rats fed the deﬁned diets indicated that both Cu
limitation and sucrose consumption, similar to theWestern diet, alter
physiological functions promoting NAFLD or NASH conditions. These
results support the hypothesis that nutrient-induced changes in
hepatic function are driven by speciﬁc transcriptional responses, such
as hedgehog and FGFs, which promote ﬁbrosis, and the differential
expressions of gene transcripts related to lipidmetabolism and altered
lipid synthesis. Histologic features and lipid accumulation were most
pronounced in the combined Cu deﬁcient and 30% sucrose diet, where
differentially expressed transcripts involved predominantly genes
belonging to primary metabolism.
Elemental analysis of serum and liver tissue indicated that serum
and hepatic Cu levels were within the expected ranges for rats fed
Cu-adequate diets [48,49], while the Cu-deﬁcient diets signiﬁcantly
reduced hepatic and serumCu levels (Fig. 5A, B). An increase in liver Fe
was observed in CuD fed rats, with no statistically signiﬁcant change in
serum Fe at either sucrose level (Fig. 5C, D). The data also suggested an
inﬂuence of sucrose on Cu levels. However, these differences were not
statistically signiﬁcantwhen correcting formultiple comparisonswith
a 95% conﬁdence interval in the experiments. These results conﬁrm
that Cu inﬂuences Fe status, which is consistent with other studies in
rats as well as observations in NAFLD patients with low serum and
liver Cu. These data thus indicate that hepatic Fe retention resulting in
serum/liver partitioning of metals occurs when dietary Cu is low,
similar to genetic inactivation of intestinal Cu uptake [27].
3.6. Moderate sucrose consumption and low dietary Cu promote
biochemical responses consistent with MetS and lipid peroxidation
Since diets low in Cu, high in sucrose or both promoted speciﬁc
transcriptional responses consistent with NAFLD and MetS, as well as
in some steatohepatitis, we tested the hypothesis that speciﬁc geneexpression alterations would result in biochemical changes consistent
with NAFLD and MetS.
Insulin resistance is considered a key indicator of MetS andmay be
observed even in the absence of obesity. While there were no
signiﬁcant differences in serum glucose across diets (Fig. 6A),
signiﬁcant hyperinsulinemia was observed in rats fed the CuD/30%
diet (Fig. 6B). A modiﬁed version of HOMA-IR veriﬁed speciﬁcally for
Wistar rats [42] was applied for the serum glucose and insulin data
from all diets. As only the CuD/30% diet showed signiﬁcant
hyperinsulinemia, the HOMA-IR values for rats fed the CuD/30% diet
were compared to the control diet [43]. The CuD/30% diet signiﬁcantly
increased the HOMA-IR value (Padj=.0262) above that of the control,
placing it within the established range for insulin resistance in Wistar
rats (Fig. 6C). Thus, the combination of high dietary sucrose and lowCu
synergistically contribute to the development of insulin resistance as a
result of hyperinsulinemia.
Hepatic and serum MDA levels were investigated as an indirect
measure of lipid peroxidation/oxidative stress, together with analysis
of ALT level as an indicator of liver damage. While hepatic MDA levels
were signiﬁcantly increased in rats fed CuD/10% and CuD/30% diets
(Fig. 6D), only a mild but relatively insigniﬁcant increase was found
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oxidative stress. SerumMDA and ALT concentrationswere found to be
signiﬁcantly higher in the CuD/30% diet vs. the CuA/10% control diet
(Fig. 6E–F). These results indicate that the CuD/10% diet is sufﬁcient to
cause increased oxidative stress and that dietary CuD concurrent with
30% dietary sucrose induces oxidative stress and mild liver damage.
4. Discussion
4.1. Cu and sucrose nutrition influence specific gene expression
consistent with NAFLD spectrum
The primary conceptual advance of this study is that the common
dietary factors, moderate sucrose consumption and suboptimal
dietary Cu, induce speciﬁc inﬂammation and ﬁbrosis transcriptional
responses in the liver, even in the absence of obesity or severe
steatosis. These inﬂammatory and ﬁbrosis responses are accompanied
by altered lipid metabolism, while Cu deﬁciency appears to drive
hepatic lipid accumulation. Our data also suggest that sucrose
consumption consistent with the Western diet disrupts Cu homeo-
stasis. This indicates that diet composition, independent of quantity,
may be a critical factor in NAFLD and progression to NASH. More
broadly, our results indicate that dietary Cu content, in addition to
sucrose (or fructose), may be a general effector of inﬂammatory
responses consistent with NAFLD disease progression, possibly
inﬂuencing broader pathologies in MetS.
Notably, the transcriptomic proﬁles and biochemical indication of
NASH in our mature rat model occurred without the dramatic
physiological changes that accompany diet treatments in weanling
rats (where Cu deﬁciency may have a much greater effect due to
developmental demands), and without the extreme levels of fructose
feeding and/or obesity inmanyWesternizedDietmodels (reviewed in
Ref. [50]). Without signiﬁcant weight gain and with only modest
steatosis and a lack of increased serum FFA levels (all of which
associated with NAFLD and obesity models, but not necessarily of
NASH), we observed changes at both the transcriptome and
physiological levels that are characteristic of NASH pathology. For
example, in our study, we identiﬁed up-regulation of gene transcripts
that are associatedwithNASHandMetS and have been documented in
both animal and clinical studies includingACE in the promotion ofHSC
activation [2,51] and association with MetS [5,52–54]. Similarly, up-
regulation of LAMA1 has been correlated with NASH and cardiovas-
cular disease in clinical settings [52], while LCN2 and STEAP2 have
been associated with altered iron metabolism and systemic inﬂam-
matory status [55–58]. CYP8B1, whose transcript expression is down-
regulated in the CuA/30% and CuD/30% diets, is involved in bile acid
synthesis. Its gene transcript has also been found to be expressed at
lower levels in clinical transcriptomic studies of NASH [59].
Whilemuch research to date has focused on the causative role that
nutrient factors in theWestern diet play in the development of hepatic
steatosis, it has been suggested that inﬂammation can precede
steatosis in some cases [19]. Induction of transcript expressions
leading to inﬂammation andﬁbrosis, despite onlymild steatosis, is one
of the most surprising results of this study. Our nutrient-associated
transcript expression proﬁles indicate that HSC activation occurs
together with activation of ECM remodeler proteins, FGFs and Tgfβ2,
as well as myosin isoforms that are related to increase in contractility/
migration of activated HSCs. Other studies in both rats and humans
indicated that increased expression of GFAP may serve as an early
marker for HSC activation during hepatitis C infection and can be used
as a predictor for ﬁbrosis progression, although its expression
decreases as ﬁbrosis progresses [60,61]. Additionally, SOCS1 may
promote HSC resistance to elimination by natural killer cells [62].
Speciﬁcally analyzing hepatic tissue, the inﬂammation-induced
activation of the HSCs may occur via the Hedgehog signaling pathwayand GLI transcription factor-induced epithelial-to-mesenchymal
transition (EMT), causing HSCs to behave as collagen-depositing
myoﬁbroblasts [63,64]. Although it has not yet been determined
whether the TGFB2 isoform inﬂuences hepatic ﬁbrosis via HSC
activation, this protein has been shown to play a causal role in models
of renalﬁbrosis [65] and is implicated in the induction of EMT in tumor
cells in vitro [66].
Although the extent of differential transcript expression observed
in response to the CuD/30% sucrose diet was limited compared to the
single-factor diets, its transcriptomic proﬁle shared several patterns of
up-regulated proﬁbrotic transcripts with the single-variable diets,
including differential gene expression of GLI1, FGFs 5 and 11, and
myosin isoformsMYH3 andMYL7. However, rats fed the CuD/30% diet
did undergo physiological and transcriptional changes indicative of
NAFLD and possibly NASH, including signiﬁcant increases in serum
ALT consistentwith liver damage and insulin resistance, both of which
are strongly associated with NAFLD to NASH progression [15,67].
4.2. Cu and dietary sucrose as modifiers of metabolic pathways
In contrast to inﬂammation and ﬁbrosis, patterns of primary
metabolic pathway alterations seemed similar across diets. Dietary
CuD and sucrose both independently and in combination resulted in
the up-regulation of GAPDH and PFKFB3 gene transcripts, with both
enzymes being involved in citrate accumulation. These suggested a
potential increase in the rate of glycolysis as a result of CuDdietswith a
resulting increase in acetyl-CoA production. The CuD diets seemed to
result in the altered expression of gene transcripts whose gene
products would further increase mitochondrial acetyl-CoA levels,
including pyruvate dehydrogenase (PDHA2) in the CuD/10% diet,
while down-regulation of carnitine O-acetyltransferase (CRAT) in the
CuD/30% diet could attenuate the normal decrease of acetyl-CoA
during O-carnitine production. Increased acetyl-CoA (as a result of
varied processes) can proceed to a mitochondrial buildup of citrate
and the resulting shuttling of excess citrate out of the mitochondria
into cytosol, whereby it is converted back into acetyl-CoA by action of
ACLY. This process serves as a metabolic connection between
carbohydrate and lipid metabolism when production of fatty acids
by FASN is needed, as well as through action of the mevalonate
pathway as an entry into cholesterol synthesis [68–70]. This increase
in fatty acid synthesismaynot necessarilymanifest itself in an increase
of circulating FFAs. Rather, FFAs synthesized in the liver may be
converted to TG and accumulate (causing steatosis, as observed with
our low-Cu diets) or be secreted as very low density lipoprotein
[71,72]. Notably, the combined CuD/30% diet uniquely up-regulated
both ACLY and FASN, indicating that CuD and sucrose each contribute
to the buildup of citrate and that the two diets act synergistically to
lead to an increase in transcript levels of genes coding for enzymes
associated with fatty acid synthesis. The observed increase in
transcripts coding for lipases, commonly expressed by Kupffer cells
[73], suggests TG breakdown within the hepatic tissue and potential
contribution to increased FFA ﬂux from hepatic tissue into serum over
time. Therefore, the up-regulation of the ACLY and FASN transcripts in
the liver suggests a mechanism for steatosis and hepatic lipotoxicity
independent of adipose lipolysis.
5. Conclusions
In conclusion, our nutrigenomics approach in themature ratmodel
allowed for unique insight intohowspeciﬁc factors in theWesterndiet
can inﬂuence gene expression to promote steatosis and NAFLD
spectrum conditions. Speciﬁcally, the approach allowed us to identify
and specify changes in gene expression observed in response to the
experimental diets, speciﬁcally in lipidmetabolism andﬁbrosis, which
provide molecular-level connections between diet and NAFLD-like
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pathogenic mechanisms behind NAFLD when compared to high-fat-
diet models, as the increasing prevalence of NAFLD in Western
cultures parallels the increase in carbohydrate and simple sugar
consumption, whereas caloric contribution of fats has declined
[74,75]. This is the ﬁrst study to our knowledge that examines
differential gene expression responses to Western diet relevant sugar
consumption and Cu deﬁciency in a mature rodent model. Results
from our study conﬁrm that inadequate dietary Cu can signiﬁcantly
inﬂuence hepatic lipid metabolism gene expression, a response that
manifests as hepatic lipid accumulation. Further, we found that
inﬂammation and ﬁbrosis gene expression are promoted by inade-
quate Cu and high sugar evenwithout severe steatosis described in the
lipotoxicity model of NAFLD progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jnutbio.2015.04.009.
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